HUE060791T2 - Antigén peptidek rák megelõzésére és kezelésére - Google Patents

Antigén peptidek rák megelõzésére és kezelésére

Info

Publication number
HUE060791T2
HUE060791T2 HUE19716176A HUE19716176A HUE060791T2 HU E060791 T2 HUE060791 T2 HU E060791T2 HU E19716176 A HUE19716176 A HU E19716176A HU E19716176 A HUE19716176 A HU E19716176A HU E060791 T2 HUE060791 T2 HU E060791T2
Authority
HU
Hungary
Prior art keywords
cancer
prevention
treatment
antigenic peptides
antigenic
Prior art date
Application number
HUE19716176A
Other languages
English (en)
Inventor
Laurent Chene
Christophe Bonny
Francesco Strozzi
Original Assignee
Enterome S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome S A filed Critical Enterome S A
Publication of HUE060791T2 publication Critical patent/HUE060791T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE19716176A 2018-04-11 2019-04-11 Antigén peptidek rák megelõzésére és kezelésére HUE060791T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305444 2018-04-11
EP2018077512 2018-10-09

Publications (1)

Publication Number Publication Date
HUE060791T2 true HUE060791T2 (hu) 2023-04-28

Family

ID=66092357

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19716176A HUE060791T2 (hu) 2018-04-11 2019-04-11 Antigén peptidek rák megelõzésére és kezelésére

Country Status (18)

Country Link
US (1) US12016910B2 (hu)
EP (2) EP4169528A1 (hu)
JP (2) JP7384819B2 (hu)
CN (1) CN112118863A (hu)
AU (1) AU2019253217A1 (hu)
BR (1) BR112020020780A2 (hu)
CA (1) CA3094262A1 (hu)
DK (1) DK3773689T3 (hu)
ES (1) ES2935702T3 (hu)
FI (1) FI3773689T3 (hu)
HR (1) HRP20230007T1 (hu)
HU (1) HUE060791T2 (hu)
LT (1) LT3773689T (hu)
MX (2) MX2020010701A (hu)
PL (1) PL3773689T3 (hu)
RS (1) RS63873B1 (hu)
SI (1) SI3773689T1 (hu)
WO (1) WO2019197567A2 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11478537B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
EP3522917A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
HUE065075T2 (hu) 2019-11-15 2024-04-28 Enterome S A Antigén peptidek B-sejtes malignitás megelõzésére és kezelésére
CN111197040B (zh) * 2020-01-21 2023-08-08 福建亿彤生物科技有限公司 壳多糖酶3样蛋白1（chi3l1）抗原表位肽、抗原、抗体、用途及试剂盒
WO2023187127A1 (en) * 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
IT202200006785A1 (it) * 2022-04-06 2023-10-06 Istituto Naz Tumori Irccs Fondazione G Pascale Analoghi di antigeni tumorali da microbiota e usi relativi
WO2024025397A1 (ko) * 2022-07-29 2024-02-01 주식회사 엘지화학 항원 전달용 재조합 융합 단백질 및 이의 이용

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1880735A3 (en) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2001062776A1 (en) 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
WO2003092717A1 (en) 2002-03-22 2003-11-13 The Penn State Research Foundation Cancer immunotherapy
EP1578432A4 (en) 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
WO2005076001A2 (en) 2004-02-06 2005-08-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
US20120052080A1 (en) 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
BRPI0720280A2 (pt) 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
EP4032899A1 (en) * 2007-08-20 2022-07-27 Oncotherapy Science, Inc. Foxm1 peptide and medicinal agent comprising the same
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
WO2010018136A1 (en) 2008-08-12 2010-02-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
EP2500350B1 (en) * 2009-11-03 2018-08-15 Korea University Research And Business Foundation Composite of a protein comprising zinc oxide-bonding peptides and zinc oxide nanoparticles, and use thereof
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
US20140371302A1 (en) 2011-12-29 2014-12-18 Modema Therapeutics, Inc. Modified mrnas encoding cell-penetrating polypeptides
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
EP3431997B1 (en) 2012-03-19 2021-07-14 Stemline Therapeutics Inc. Methods for treating and monitoring the status of cancer
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
EP3912634B1 (en) * 2012-05-16 2023-10-04 Stemline Therapeutics Inc. Cancer stem cell targeted cancer vaccines
US20140141044A1 (en) 2012-11-12 2014-05-22 Dana-Farber Cancer Institute, Inc. Cord Colitis Syndrome Pathogen
KR20180049238A (ko) 2012-12-05 2018-05-10 솔라 바이오사이언시즈 엘엘씨 단백질 발현 증진 폴리펩타이드
CA2893918C (en) 2012-12-06 2020-11-24 Callaghan Innovation Research Limited Conjugate compounds
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
WO2015185067A1 (en) * 2014-06-06 2015-12-10 Herlev Hospital Determining antigen recognition through barcoding of mhc multimers
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
US20180078627A1 (en) 2015-03-31 2018-03-22 Agency For Science, Technology And Research Method for antigen loading of dendritic cells and vaccine
EP3464630A1 (en) 2016-05-23 2019-04-10 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods of diagnosing cancer using cancer testis antigens
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
US11478537B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
EP3522917A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
US20200256877A1 (en) 2017-10-09 2020-08-13 Enterome S.A. Microbiota Sequence Variants Of Tumor-Related Antigenic Epitopes
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
HUE065075T2 (hu) 2019-11-15 2024-04-28 Enterome S A Antigén peptidek B-sejtes malignitás megelõzésére és kezelésére

Also Published As

Publication number Publication date
CA3094262A1 (en) 2019-10-17
WO2019197567A2 (en) 2019-10-17
JP7384819B2 (ja) 2023-11-21
WO2019197567A3 (en) 2019-11-28
AU2019253217A1 (en) 2020-10-15
BR112020020780A2 (pt) 2021-03-02
JP2021520818A (ja) 2021-08-26
MX2020010701A (es) 2021-01-20
US20210113678A1 (en) 2021-04-22
MX2023014457A (es) 2023-12-15
SI3773689T1 (sl) 2023-02-28
EP3773689B1 (en) 2022-11-09
US12016910B2 (en) 2024-06-25
PL3773689T3 (pl) 2023-03-13
LT3773689T (lt) 2023-01-25
RS63873B1 (sr) 2023-02-28
EP3773689A2 (en) 2021-02-17
JP2024016203A (ja) 2024-02-06
EP4169528A1 (en) 2023-04-26
HRP20230007T1 (hr) 2023-03-03
DK3773689T3 (da) 2023-01-16
CN112118863A (zh) 2020-12-22
ES2935702T3 (es) 2023-03-09
FI3773689T3 (fi) 2023-01-31

Similar Documents

Publication Publication Date Title
FI3773689T3 (fi) Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
HK1252873A1 (zh) 用於癌症治療和預防的疫苗
IL276808A (en) Preparations and methods for the treatment of cancer
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
IL279347A (en) Gremlin-1 antagonist for cancer prevention and treatment
IL268814A (en) Preparations and methods for the treatment of cancer
RS65262B1 (sr) Antigenski peptidi za prevenciju i lečenje maligniteta b ćelija
IL286297A (en) Minimal residual cancer treatment methods
SG11202011117VA (en) Treatment of cancer
SG11202006160RA (en) Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer
GB201812647D0 (en) Viral vectors and methods for the prevention or treatment of cancer
IL272147A (en) Methods and preparations for the treatment of cancer
LT3630112T (lt) Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymui
IL280262A (en) Compositions and methods for treating cancer
GB201810635D0 (en) Peptides and cancer treatment
PT4021487T (pt) Péptidos antigénicos para prevenir e tratar neoplasia maligna de células b
GB201815694D0 (en) Prevention and treatment of cancer
GB201809946D0 (en) Prevention and treatment of cancer
IL281091A (en) Peptide therapy for cancer treatment and their uses
IL262945A (en) Medicament for treatment and/or prophylactic treatment of breast cancer
IL288433A (en) Peroxidase-3 activation and immunotherapy for cancer treatment
IL277313A (en) Sposin C Pharmaceuticals and Cancer Treatment Methods
IL277112A (en) Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer
IL281782A (en) Drug combination for cancer treatment
GB201820975D0 (en) Methods of cancer treatment